Generic Name and Formulations:
Estradiol 0.025mg/day, 0.05mg/day, 0.075mg/day, 0.1mg/day; transdermal system.
Indications for ALORA:
Moderate to severe vasomotor symptoms of menopause. Vulval and vaginal atrophy. Postmenopausal osteoporosis prevention. Hypoestrogenism.
Apply to clean, dry area on lower abdomen, hips, or buttocks (avoid breasts, waistline). Rotate application sites. Osteoporosis: initially 0.025mg/day twice weekly; may increase as needed based on BMD. Others: initially 0.05mg/day twice weekly. Maintenance: use lowest effective dose. Patients without intact uterus may use continuous schedule; otherwise use cyclically (3 weeks on, 1 week off). Transferring from other topical therapy: may start immediately or if from oral estrogens: apply 1st system up to 1 week after last oral dose.
Undiagnosed abnormal genital bleeding. Thromboembolic disorders (eg, DVT, PE, stroke, MI). Thrombophlebitis. Breast or other estrogen-dependent neoplasms. Hepatic disease. Pregnancy (Cat.X).
Cardiovascular disorders. Endometrial cancer and breast cancer. Probable dementia.
Increased risk of endometrial carcinoma or hyperplasia in women with intact uterus (adding progestin is essential). Not for prevention of cardiovascular disease or dementia. Increased risk of cardiovascular events (eg, MI, stroke, VTE); discontinue if occurs. Manage risk factors for cardiovascular disease and venous thromboembolism appropriately. Discontinue at least 4–6 weeks before surgery type associated with increased risk of thromboembolism or during prolonged immobilization. Increased risk of breast or ovarian cancer. Risk of probable dementia in women >65yrs of age. Gallbladder disease. Severe hypercalcemia in breast cancer or bone metastases. Visual abnormalities. History of hypertriglyceridemia. Discontinue if cholestatic jaundice, hypercalcemia, or retinal vascular lesions occur. Monitor thyroid function. Conditions aggravated by fluid retention. Endometriosis. Severe hypocalcemia. Asthma. Diabetes. Epilepsy. Migraine. Porphyria. SLE. Hepatic hemangiomas. Do initial complete physical and repeat annually (include Pap smear, mammogram, and BP). Reevaluate periodically. Nursing mothers.
Concomitant thyroid replacement; may need to increase thyroid dose. May interfere with lab tests (eg, thyroid, PT, coagulation factors, glucose tolerance, HDL/LDL, triglycerides, hormone concentrations, other binding or plasma proteins).
Headache, pain, nausea, dyspepsia, dizziness, mastodynia, local irritation, migraine, vaginal bleeding (at 0.1mg/day dose); thromboembolism, neoplasms.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Rapid Cycling in Bipolar Disorder: Overview and Expert Perspectives
- Early Childhood Out-of-Home Placement Associated With Adverse Outcomes in Adulthood
- Tolerability of Novel Long-Acting Injectable Aripiprazole Tested for Bipolar Disorder
- Coping Strategies for Amplified Emotionality May Improve Bipolar Disorder Symptoms
- Link Between Vitamin D Levels and Intracranial Volume in Schizophrenia
- The Psychology of Hoarding Disorder: Approaches for Treatment
- Mind-Body Therapy and Psychiatry: Ancient Tools for Modern Practice
- Smartphone Applications for Depression and Anxiety: Are They Ready for Widespread Use?
- The Many Misconceptions of Catatonia: Treatment Is Often Successful With the Right Knowledge
- Marijuana Use Associated With Poorer Depression Outcomes, Increased Suicidal Ideation
- Symptoms of Anxiety, Depression Differ Depending on Gender, Race, Ethnicity
- Examining Whether Adjunctive Glutamatergic Medication Further Eases OCD Symptoms
- FDA Permits Marketing of Brain Stimulation Device for OCD
- Antipsychotics Adversely Affect Adiposity and Insulin Sensitivity in Youths
- Know Before You Go: Practicing Medicine Abroad